The contract will see PRECOS provide clinical tumour material, tumour model development, target validation and drug efficacy work to support Janssen’s oncology drug discovery, development and biomarker programmes.
PRECOS was launched as a spin-off from the University of Nottingham, UK in August 2010 and it offers patient-relevant models which closely reflect the patient situation for each aspect of cancer progression encompassing pre-cancerous lesions, primary tumours and metastasis.
PRECOS chief scientific officer Sue Watson said that this global contract further strengthens the long term relationship between PRECOS and Janssen and consolidates PRECOS’ evolution from a primarily academic background into an ambitious commercial entity, offering significant scientific expertise and delivering specialist services in the development of new anti-cancer drugs.
Janssen Research & Development Global Oncology Research head Martin Page said that their agreement with PRECOS is a natural extension of their relationship with the University of Nottingham.